Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person pexidartinib-resistant FLT3 mutants don't bind pexidartinib

Class:IdFailedReaction:9702607
_displayNamepexidartinib-resistant FLT3 mutants don't bind pexidartinib
_doReleaseTRUE
_timestamp2020-11-06 20:56:19
authored[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
compartment[Compartment:876] plasma membrane
created[InstanceEdit:9702606] Rothfels, Karen, 2020-10-01
disease[Disease:1500689] cancer
edited[InstanceEdit:9706566] Rothfels, Karen, 2020-11-06
entityFunctionalStatus[EntityFunctionalStatus:9702608] loss_of_function of pexidartinib-resistant FLT3 mutants [plasma membrane]
input[DefinedSet:9699534] pexidartinib-resistant FLT3 mutants [plasma membrane] [Homo sapiens]
[ChemicalDrug:9677649] pexidartinib [cytosol]
isChimericFALSE
literatureReference[LiteratureReference:9699279] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
[LiteratureReference:9703039] Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
[LiteratureReference:9695648] Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
[LiteratureReference:9699393] Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
modified[InstanceEdit:9703028] Rothfels, Karen, 2020-10-03
[InstanceEdit:9703079] Rothfels, Karen, 2020-10-05
[InstanceEdit:9704328] Rothfels, Karen, 2020-10-07
[InstanceEdit:9706570] Rothfels, Karen, 2020-11-06
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namepexidartinib-resistant FLT3 mutants don't bind pexidartinib
normalReaction
releaseDate2020-12-08
reviewed[InstanceEdit:9706568] Kazi, Julhash U, 2020-11-06
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9702610] R-HSA-9702607.2
summation[Summation:9703026] The following FLT3 mutants are resistant to inhibition by pe...
(hasEvent)[Pathway:9702605] pexidartinib-resistant FLT3 mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by pexidartinib-resistant FLT3 mutants don't bind pexidartinib (9702607)
Follow Reactome